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A B S T R A C T
Balanoposthitis is deﬁned as the inﬂammation of the glans penis and its foreskin. In the presence of other
underlying medical conditions, this localized infection may spread systemically, serving as a source of
fever and bacteremia in neutropenicmales. Two rare cases of balanoposthitis caused by a clonally related
Pseudomonas aeruginosa isolate co-producing the SPM-1 metallo-b-lactamase and the novel 16S rRNA
methylase RmtD are described. Four multidrug-resistant (MDR) P. aeruginosa isolates were successively
recovered from glans/foreskin swabs and urine cultures from two uncircumcised pediatric patients, one
with Burkitt’s non-Hodgkin’s lymphoma and one with acute lymphoblastic leukemia. Clinically,
preputial colonization by MDR P. aeruginosa evolved to severe balanoposthitis with glans/foreskin
lesions as a source of fever. Combination therapy of ciproﬂoxacin and/or aztreonam (systemic) plus
polymyxin B (topical) was effective once reversion of the neutropenic condition was achieved. Although
P. aeruginosa remains an unusual cause of balanoposthitis, these cases should alert the physician to the
potential pathogenicity of this bacterium. Furthermore, co-production of metallo-b-lactamase and 16S
rRNA methylase has a potential impact on the empirical management of complicated infections caused
by P. aeruginosa.
Crown Copyright  2009 Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. All rights reserved.
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Balanoposthitis is deﬁned as the inﬂammation of the glans
penis and its foreskin. A wide variety of infectious causes and
predisposing factors have been described, and the condition is
more common among uncircumcised men, possibly as a result of
poorer hygiene, limited retraction of the foreskin, or due to
irritation by smegma.1 In the presence of other underlyingmedical
conditions, this localized infection may spread systemically,
serving as a source of fever and bacteremia in neutropenic males.2
Even though the cause often remains undiagnosed, it is known that
many cases are caused by infection with Candida spp. On the other
hand, infection with Gardnerella vaginalis and anaerobes are
common, especially when sexually transmitted.1,3 Group B and
group A streptococci have also been reported to cause balano-
posthitis. Other known causes include Staphylococcus aureus,* Corresponding author. Tel.: +55 11 3091 7296; fax: +55 11 3091 7354.
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doi:10.1016/j.ijid.2009.04.016Treponema pallidum, Chlamydia trachomatis, Neisseria gonorrhoeae,
Mycoplasma spp, plus some viral and parasitic causes.1,3–6 As to
balanoposthitis caused by P. aeruginosa, there are only three case
reports that can be found in the medical literature (PubMed
database). One report describes balanoposthitis due to P.
aeruginosa diagnosed in a neutropenic patient who underwent
immunosuppressive therapy,2whereas the other reports describe
a case of erosive pseudomonal balanitis that developed during
treatment with topical antibacterial, antifungal, and corticoster-
oid agents, and isolated gangrenous lesions in a male child with
acute leukemia and granulocytopenia in the setting of P.
aeruginosa bacteremia.7,8 Herein we report two rare cases of
balanoposthitis caused by multidrug-resistant (MDR) P. aerugi-
nosa, in uncircumcised pediatric patients with underlying
hematological malignancy.
2. Case reports
The Centro Infantil Boldrini (CIB) is a pediatric hematology–
oncology hospital in Campinas, Southeastern Brazil. This institution,Ltd on behalf of International Society for Infectious Diseases. All rights reserved.
Figure 1. Necrotizing balanoposthitis due to Pseudomonas aeruginosa co-producing
SPM-1 metallo-b-lactamase and 16S rRNA methylase RmtD in a pediatric patient
with acute lymphoblastic leukemia (case 2). In the picture, a dark black necrotizing
ring at the tip of foreskin is observed.
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center for the region. The majority of patients hospitalized at the
CIB are on chemotherapy for solid tumors and leukemias and the
neutropenic condition of these in-patients is associated with
various levels of myelosuppression resulting from the disease
and/or indirectly induced by chemotherapy.
2.1. Case 1
On May 3, 2004, a 5-year-old male patient with Burkitt’s non-
Hodgkin’s lymphoma, on consolidation chemotherapy, was
admitted to the CIB due to septic shock. He had previously been
hospitalized at the same center for short-term chemotherapy and
because of two episodes of fever and neutropenia, which were
treated empirically with a 10-day course of ceftriaxone (80 mg/kg
every 24 h) and a 7-day course of ceftazidime (50 mg/kg every 8 h).
On physical examination on this admission, hypotension, tachy-
cardia, anuria, jaundice, and foreskin edema and erythema were
noticed, and severe neutropenia was observed. A set of blood and
surveillance swab cultures, including of the foreskin, were
collected and the patient was transferred to the pediatric intensive
care unit (PICU). Treatments involved volume replacement with-
out vasoactive drugs, which was effective in improving the
hemodynamic parameters and in re-establishing diuresis, and
empiric antibiotic therapy with ceftazidime (50 mg/kg every 8 h),
amikacin (20 mg/kg every 24 h), and vancomycin (10 mg/kg every
6 h). On the second day after admission, the patient developed
severe balanoposthitis with cellulitis, erythema and swelling of the
glans/foreskin, and persistent fever. On the third day after
admission, without antibiotic change, the patient showed clinical
improvement as a result of bone marrow recuperation, monitored
by white blood cell (WBC) count. An MDR P. aeruginosa strain,
sensitive only to aztreonam (strain CIB 518), was unexpectedly
recovered from the foreskin swab culture (Table 1). Blood cultures
were negative. During the following three days, the patient did not
present fever and the swelling of the glans/foreskin began to
subside, thus, he was transferred to the ward before being
discharged.
On June 11, after a new session of chemotherapy he was
readmitted to the CIB presenting with neutropenia, fever, and
upper respiratory tract infection. Fever was attributed to viral
infection and the patient, being considered in the low-risk group,
was treated with ceftriaxone (100 mg/kg every 24 h). On the
second day, swelling, redness, pain, and purulent secretion on the
foreskin were noted and antibiotic therapy was changed to
ceftazidime (50 mg/kg every 8 h). Samples from glans secretion
and midstream urine were collected for culture, and two further
MDR P. aeruginosa isolates (strains CIB 704 and 904) were
recovered (Table 1). Due to the scarcity of an antimicrobial option,
combination therapy using ciproﬂoxacin (10 mg/kg every 12 h)
plus topical polymyxin B was initiated. This therapeutic regimen
proved to be clinically successful; however, it must be pointed out
that during this combination therapy the patient was not
neutropenic, marrow recovery having been achieved during
consolidation chemotherapy, as observed by hematological
evaluation. Finally, on June 17, the patient was discharged home
having successfully completed chemotherapy.
2.2. Case 2
On July 12, 2004, a 9-year-old boy with acute lymphoblastic
leukemia (ALL), on a second induction chemotherapy regimen due
to high risk for early relapse of his ALL, was admitted to the CIB
with neutropenic fever and pain on his penis. During the previous
months he had been hospitalized three times at the CIB. The ﬁrst
admission was for neutropenic fever associated with cellulitis andbacteremia caused by Staphylococcus aureus, which was success-
fully treated with cefazolin and amikacin. The latter two
admissions were due to mucositis and herpes zoster infection
plus bacteremia with Acinetobacter baumannii. Mucositis was
treated with cefazolin and amikacin (20 mg/kg every 8 h and
20 mg/kg every 24 h, respectively), whereas the A. baumannii
bacteremia was treated with amikacin and ceftazidime (20 mg/kg
every 24 h and 50 mg/kg every 8 h, respectively). On this
admission, two blood samples were collected for bacteriological
culture, and antibiotic therapy was started with cefazolin (20 mg/
kg every 8 h) and amikacin (20 mg/kg every 24 h). Forty-eight
hours after admission, the patient developed severe balanoposthi-
tis with cellulitis and erythema.Moreover, the local lesion began to
extend to the pubic region. Even though blood cultures were
negative, fever and neutropenia were persistent, thus, additional
blood samples and glans/foreskin swabs were collected and the
antibiotic regimen was changed to ceftazidime (50 mg/kg every
8 h) andmetronidazole (7.5 mg/kg every 6 h). On the ﬁfth day after
admission, glans and foreskin necrotizing lesions were observed
(Figure 1) and his clinical condition progressively worsened. On
physical examination, hypotension, tachycardia, and oliguria were
noted. When the patient developed septic shock related to
Fournier’s gangrene and neutropenia, he was transferred to the
PICU, where antibiotic therapy was changed to imipenem (15 mg/
kg every 6 h), and volume replacement therapy and dopamine
(5 mg/kg/min) were initiated. From the second set of samples
collected for microbiological culture, an MDR P. aeruginosa isolate
(strain CIB 940) with susceptibility only to aztreonam and colistin
was recovered exclusively from the glans and penis foreskin; blood
samples remained negative (Table 1). On the sixth day, secretion
with blood from the foreskin necrotic lesion was observed and the
local foreskin/glans swelling extended to the total pubic and
scrotal area. Due to scarcity of a therapeutic option, imipenemwas
changed to a combination therapy of ciproﬂoxacin and aztreonam
(systemic administration of 10 mg/kg every 12 h and 30 mg/kg
every 6 h, respectively) and topical polymyxin B ointment, in an
attempt to achieve a synergistic effect. At this point, the patient
presented an increase in WBC count indicating bone marrow
Table 1
Epidemiological and microbiological data for the multidrug-resistant Pseudomonas aeruginosa isolates
Strain Source Date (m/d/y) Minimum inhibitory concentration (mg/ml) PCR assay ERIC proﬁle
IMP IMP/EDTA CAZ ATM AMK CIP PXB
CIB 518 Glans swab 05/04/04 >256 6 >256 2 >256 >32 <4 blaSPM-1, rmtD A
CIB 704 Urinea 06/14/04 >256 6 >256 3 >256 >32 <4 blaSPM-1, rmtD A
CIB 904 Glans swab 06/14/04 >256 4 >256 4 >256 >32 <4 blaSPM-1, rmtD A
CIB 940 Glans swab 07/16/04 128 2 >256 3 >256 >32 <4 blaSPM-1, rmtD A
AMK, amikacin; ATM, aztreonam; CIP, ciproﬂoxacin; CAZ, ceftazidime; EDTA, ethylenediaminetetraacetic acid; IPM, imipenem; PXB, polymyxin B.
a Urine, 50 000 cfu/ml.
N. Lincopan et al. / International Journal of Infectious Diseases 14 (2010) e344–e347e346recovery. The administration of dopamine was brought to an end
and the patient was transferred to the ward due to fever not being
present during the latter 48 hours. On July 26 (at day 14 after
admission), the patient, being considered clinically recovered, was
discharged home. Two months later, complete healing of the
foreskin/glans lesions was attained.
2.3. Isolates identiﬁed
The four isolates of P. aeruginosa were identiﬁed by the Vitek
system (BioMe´rieux, Hazlewood, MO, USA). Minimum inhibitory
concentrations (MICs) were determined by E-test (AB Biodisk,
Solna, Sweden). Next, metallo-b-lactamase (MBL) production was
screened by a double disk-synergy test using ceftazidime and
imipenem as substrates and ethylenediaminetetraacetic acid
(EDTA) and thiol compounds [2-mercaptoacetic acid (2-MAA)
and 2-mercaptopropionic acid (2-MPA)] asb-lactamase inhibitors.
The enhancement of inhibition zone or the presence of a key hole
(or ghost zone) between imipenem- or ceftazidime-containing
disk and EDTA- or thiol compound-containing diskwas interpreted
as a positive result to MBL production.9 DNA ampliﬁcation by PCR
was used to search for speciﬁc blaIMP, blaVIM, and blaSPM MBL
genes.10 Additionally, aminoglycoside-resistance was investigated
by PCR for the armA, rmtA, rmtB, rmtC, and rmtD 16S rRNA
methylase genes.11
All isolates recovered presented the unusual antibiogram
phenotype of resistance to all b-lactams except aztreonam, and
were also resistant to all the other antibiotics available such as
aminoglycosides and ﬂuoroquinolones. Thehigh levels of imipenem
resistance (128mg/ml) observed in these P. aeruginosa isolates
suggested the presence of an MBL, since these enzymes are
considered to be the most frequent cause of carbapenem resistance
in these organisms.12 MBL activity was conﬁrmed by the double-
disk test, but ghost zones were observed exclusively between 2-
MAA-containing disks and ceftazidime-containing disks. Moreover,
there was a reduction in the MIC of imipenem in the presence of
EDTA, from a range of 128 down to 6mg/ml, indicating MBL
activity (Table 1). PCR analysis showed that all isolates harbored
both the blaSPM and rmtD genes, which were responsible for
resistance to all beta-lactams and aminoglycosides, respectively.
Using the ERIC-2 primer,13 genotyping revealed that the isolates
were clonally related (Table1), all presenting identical bandproﬁles.
3. Discussion
Pseudomonas aeruginosa is one the most frequent pathogens in
neutropenic patients.14 Combination therapy is normally recom-
mended for the treatment of these infections because this
organism displays a decreased susceptibility to the currently used
anti-pseudomonal agents.15 Although the preferred combination
remains b-lactams and aminoglycosides, over the past few years
the frequency of resistance to these antibiotics has been higher,
especially in Brazil.16 In this regard, the emergence of isolates
producing carbapenemases, mainly MBL, have limited the use ofb-lactams;12 SPM-1 producing P. aeruginosa has been reported to
be endemic in Brazilian hospitals since 2003.10,17 Indeed, a fatal
outbreak of infection due to clonally related SPM-1 producing P.
aeruginosa was documented at our institution18 at the time when
these two cases of balanoposthitis occurred, and the four P.
aeruginosa isolates studied here were part of the cluster of the
SPM-1 producing P. aeruginosa. On the other hand, production of
16S rRNAmethylase has emerged recently as amechanism of high-
level resistance to all 4,6-disubstituted deoxystreptamine ami-
noglycosides, such as amikacin, tobramycin, and gentamicin.11
Thus, co-production of novel 16S rRNAmethylases andMBLwould
render ineffective a potent double-coverage regimen of carbape-
nem plus aminoglycoside, contributing to the emergence of
multidrug-resistant phenotypes.17
In the present study three main ﬁndings are reported. First,
balanoposthitis due to P. aeruginosa infection occurs in neutro-
penic patients and can be recurrent.3 In this regard, it is likely that
the initial colonization of the glans and its foreskin resulted from
exposure of the preputial mucosa to contaminated surfaces, or just
as likely, contaminated hands (particularly healthcare workers),
evolving to severe balanoposthitis with glans/foreskin lesions as a
source of fever. Secondly, co-production of MBL and 16S rRNA
methylase has a potential impact on the empirical management of
complicated infections caused by P. aeruginosa, which are usually
treated with cephalosporins and aminoglycosides. Thirdly, com-
bined treatment may be helpful but it should be correlated with
the reversion of the neutropenic condition. In fact, MDR P.
aeruginosa sepsis in the neutropenic patient has been successfully
treated with serial granulocyte transfusions.19 On the other hand,
MDR P. aeruginosa infection in neutropenic patients has been
successfully treated with combination therapy using polymyxin
B.20 Interestingly, none of the MBLs hydrolyze aztreonam.12 In this
regard, aztreonam has been proved to be an effective alternative
for combined treatment of Gram-negative infections and fever of
unknown origin in cancer patients,21 including those infections
caused by MBL-producing P. aeruginosa and Klebsiella pneumo-
niae.22–24 Likewise, ciproﬂoxacin has been effective against
infection with P. aeruginosa carrying blaIMP MBL in an endogenous
bacteremia model.25 However, all these reports must be regarded
as preliminary, and large, randomized controlled trials are required
to deﬁne the optimal treatment for these infections.
4. Conclusions
We report two rare cases of balanoposthitis caused by P.
aeruginosa co-producingMBL and 16S rRNAmethylase. Although P.
aeruginosa remains an unusual cause of balanoposthitis, these
cases should alert the physician to the potential pathogenicity of
this bacterium. Furthermore, co-production of MBL and 16S rRNA
methylase has a potential impact on the empirical management of
complicated infections caused by P. aeruginosa.
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